Average Insider

Where insiders trade, we follow

$IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Clay Siegall
CEO
131
Employees
$23.95
Current Price
$2.03B
Market Cap
52W Low$8.93
Current$23.9571.1% above low, 28.9% below high
52W High$30.06

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00--All Sells
Sells11$334,224.0013,200
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Sep 11, 2026
Higgins Jack
Chief Scientific Officer
Sale13,200$25.32$334,224.00View Details
38 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 10, 2026
EPS
Estimated-$0.61
Actual-$0.76
Miss
Revenue
Estimated$153.85K
ActualN/A
Nov 9, 2026
EPS
Estimated-$0.62
Actual-$0.76
Miss
Revenue
Estimated$153.85K
ActualN/A
Nov 5, 2026
EPS
Estimated-$0.60
ActualN/A
Revenue
Estimated$153.85K
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.10.12